Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533108 | 0.95 | KDM4E (0.37) | KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL48077 | 0.86 | KDM4E (0.39) | KDM4EHRH3 | |
| Oxalic Acid SCHEMBL48042 | 0.85 | KDM4E (0.38) | KDM4EMEN1KMT2AHRH3 | |
| Oxalic Acid SCHEMBL1533107 | 0.83 | KDM4E (0.41) | KDM4EHRH3 | |
| SCHEMBL48022 | 0.82 | SIGMAR1 (0.39) | ESR1 | |
| SCHEMBL48049 | 0.82 | KDM4E (0.39) | KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL48060 | 0.81 | KDM4E (0.41) | KDM4EHRH3 | |
| SCHEMBL1532985 | 0.77 | CHRNB2 (0.41) | — | |
| SCHEMBL48801 | 0.74 | LPAR5 (0.36) | KDM4ELPAR5 | |
| SCHEMBL48343 | 0.72 | CTNNB1 (0.40) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | DRD2 2617/4885DRD4 1402/4885KDM4E 766/4885 |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | DRD2 2617/4885DRD4 1402/4885KDM4E 766/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | DRD2 2617/4885DRD4 1402/4885KDM4E 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.